Cellectis: TALENTM Technology: Grant of EP 2 510 096 by the European Patent Office

Regulatory News :

Cellectis SA (Paris:ALCLS) (Alternext: ALCLS.PA), a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART cells (UCART), is pleased to announce the publication of the grant of European patent EP 2 510 096 by the European Patent Office to the University of Minnesota and Iowa State University Research Foundation Inc., on October 22, 2014. Cellectis has exclusive rights to this patent under an agreement entered in 2011 with the Regents of the University of Minnesota.

EP 2 510 096 is the first European patent ever granted in the field of TAL-nucleases.

About Cellectis
Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 14 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies for treating leukemias and solid tumors. Cellectis’ adoptive cancer immunotherapy for chronic and acute leukemias is based on allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.